Revenue for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current revenue (TTM) is $14.34B USD. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings (not a live revenue-per-second estimate).
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingRevenueSwitch metric
TTM (last 4 quarters)
$14.34B
YoY change
+1.0%
5Y CAGR
+11.0%
Peak year (2021)
$16.07B
Cumulative revenue
$115.14B
Revenue history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Revenue history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Revenue | YoY |
|---|---|---|---|---|
| 2025 | $14.34B | +1.0% | ||
| 2024 | $14.20B | +8.3% | ||
| 2023 | $13.12B | +7.8% | ||
| 2022 | $12.17B | -24.3% | ||
| 2021 | $16.07B | +89.1% | ||
| 2020 | $8.50B | +29.6% | ||
| 2019 | $6.56B | -2.3% | ||
| 2018 | $6.71B | +14.3% | ||
| 2017 | $5.87B | +20.8% | ||
| 2016 | $4.86B | +18.4% | ||
| 2015 | $4.10B | +45.5% | ||
| 2014 | $2.82B | +34.0% | ||
| 2013 | $2.10B | +52.7% | ||
| 2012 | $1.38B | +209.2% | ||
| 2011 | $445.82M | -2.9% | ||
| 2010 | $459.07M | +21.0% | ||
| 2009 | $379.27M | +59.1% | ||
| 2008 | $238.46M | +90.7% | ||
| 2007 | $125.02M | +97.1% | ||
| 2006 | $63.45M | -4.1% | ||
| 2005 | $66.19M | -62.0% | ||
| 2004 | $174.02M | +202.7% | ||
| 2003 | $57.50M | +161.5% | ||
| 2002 | $21.99M | +0.1% | ||
| 2001 | $21.97M | -62.9% | ||
| 2000 | $59.28M | +71.8% | ||
| 1999 | $34.50M | -9.7% | ||
| 1998 | $38.20M | +15.4% | ||
| 1997 | $33.10M | +37.3% | ||
| 1996 | $24.10M | -12.0% | ||
| 1995 | $27.40M | +18.1% | ||
| 1994 | $23.20M | +118.9% | ||
| 1993 | $10.60M | -7.8% | ||
| 1992 | $11.50M | +57.5% | ||
| 1991 | $7.30M | +46.0% | ||
| 1990 | $5.00M | — |
Revenue values are taken from Regeneron Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual revenue for Regeneron Pharmaceuticals (REGN) came in at $14.34B – edged up 1.0% year-over-year.
Through 2020–2025 (5 years), Regeneron Pharmaceuticals revenue delivered a +11.0% annualised rate; sustaining 3 straight years of year-over-year growth.
Between 2021 and 2025, Regeneron Pharmaceuticals revenue declined 10.8%, falling from $16.07B to $14.34B.
The dataset's maximum revenue sits at $16.07B (2021); the minimum reading of $5.00M dates to 1990.
Regeneron Pharmaceuticals (REGN) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $65.09B.
Regeneron Pharmaceuticals Revenue by Year
Regeneron Pharmaceuticals Revenue 2025: $14.34B
Regeneron Pharmaceuticals revenue in 2025 was $14.34B, edged up 1.0% from 2024.
Regeneron Pharmaceuticals Revenue 2024: $14.20B
Regeneron Pharmaceuticals revenue in 2024 was $14.20B, grew 8.3% from 2023.
Regeneron Pharmaceuticals Revenue 2023: $13.12B
Regeneron Pharmaceuticals revenue in 2023 was $13.12B, grew 7.8% from 2022.
Regeneron Pharmaceuticals Revenue 2022: $12.17B
Regeneron Pharmaceuticals revenue in 2022 was $12.17B, declined 24.3% below 2021.
Regeneron Pharmaceuticals Revenue 2021: $16.07B
Regeneron Pharmaceuticals revenue in 2021 was $16.07B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Revenue
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest revenue.
| Company | Revenue | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $447.57B | Healthcare |
| Novo Nordisk A/S (NVO) | $309.06B | Healthcare |
| Johnson & Johnson (JNJ) | $94.19B | Healthcare |
| Eli Lilly and Company (LLY) | $65.18B | Healthcare |
| Merck & Co., Inc. (MRK) | $65.01B | Healthcare |
| AbbVie Inc. (ABBV) | $61.16B | Healthcare |
| AstraZeneca PLC (AZN) | $58.74B | Healthcare |
| Amgen Inc. (AMGN) | $36.74B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's revenue?
- Latest reported revenue for Regeneron Pharmaceuticals (REGN) is $14.34B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals revenue changed year-over-year?
- Regeneron Pharmaceuticals (REGN) revenue changed +1.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals revenue?
- Regeneron Pharmaceuticals (REGN) revenue compound annual growth rate is +11.0% over the most recent 5 years available.
When did Regeneron Pharmaceuticals revenue hit its highest annual value?
- Regeneron Pharmaceuticals revenue reached its highest annual value of $16.07B in 2021.
What was Regeneron Pharmaceuticals revenue in 2024?
- Regeneron Pharmaceuticals (REGN) revenue in 2024 was $14.20B.
What was Regeneron Pharmaceuticals revenue in 2025?
- Regeneron Pharmaceuticals (REGN) revenue in 2025 was $14.34B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.